Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease (Q31398968)

2 July 2017

Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease (English)

1 reference

2 July 2017

Lepor NE

1

1 reference

2 July 2017

Gross SB

2

1 reference

2 July 2017

Daley WL

3

1 reference

2 July 2017

Samuels BA

4

1 reference

2 July 2017

Rizzo MJ

5

1 reference

2 July 2017

Luko SP

6

1 reference

2 July 2017

Hickey A

7

1 reference

2 July 2017

Buchbinder NA

8

1 reference

2 July 2017

Naqvi TZ

9

1 reference

2 July 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

American Journal of Cardiology

2 July 2017

1 reference

2 July 2017

86

1 reference

2 July 2017

1

1 reference

2 July 2017

107-110

1 reference

Valvular heart disease associated with fenfluramine-phentermine

2 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Quantitation of aortic regurgitation by Doppler echocardiography: a practical approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Evaluation of aortic insufficiency by Doppler color flow mapping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Quantitative assessment of mitral regurgitation by Doppler color flow imaging: angiographic and hemodynamic correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Usefulness of color Doppler proximal isovelocity surface area method in quantitating valvular regurgitation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Assessment of mitral regurgitation severity by Doppler color flow mapping of the vena contracta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Dise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900840-7

10.1016/S0002-9149(00)00840-7

7 January 2021

Identifiers

DOI

1 reference

2 July 2017

1 reference